Abstract:Insulin (INS) delivery system that can mimic normal insulin secretion to maintain the blood glucose level (BGL) in the normal range is an ideal treatment for diabetes. However, most of the existing closed-loop INS delivery systems respond slowly to the changes in BGL, resulting in a time lag between the abnormal BGL and the release of INS, which is not suitable for practical application. In this study, glucose oxidase (GOx)-modified erythrocytes are used as INS carriers (GOx-INS-ER) that can rapidly self-regulate the release of INS upon the changes in BGL. In this system, glucose can be broken down into gluconic acid and hydrogen peroxide by GOx-INS-ER, and the latter will rupture the erythrocyte membrane to release INS within minutes. A pulsatile release of INS can be achieved upon the changes in the glucose concentration. This GOx-INS-ER enables diabetic rats to overcome hyperglycemia within 1 h, and a single injection of this GOx-INS-ER into the STZ-induced diabetic rats can maintain the BGL in the normal range up to 9 days. Statement of Significance Diabetes mellitus has been a major public health threatener with global prevalence. Although, glucose responsive carriers that can release insulin (INS) in a closed loop have been explored greatly in recent years, their sluggish glucose-responsive property and low INS-loading content greatly restrict their practical application [ACS Nano, 2013, 7, 4194]. In this work, we reported INS-loaded erythrocytes featuring ultrafast glucose-responsive property and high INS loading content, which could release INS in a closed loop. These GOX-INS-ERs could respond to the changes in glucose level within several minutes and self-regulate the release of INS for a long time. Single injection of GOX-INS-ER can overcome hyperglycemia in diabetic mice within 1 h and maintain the baseline level of glucose up to 9 days. We think our method may provide a robust way to potentiate diabetes treatment. (C) 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Core-Shell Microneedle Gel for Self-Regulated Insulin Delivery.

Ultrafast Glucose-Responsive, High Loading Capacity Erythrocyte to Self-Regulate the Release of Insulin

Bioresponsive Microneedles with a Sheath Structure for H2 O2 and Ph Cascade-Triggered Insulin Delivery.

Glucose‐Responsive Microneedle Patch With Variable Crosslinking Density and Flexible Core–Shell Structure for Insulin Delivery

Intelligent Microneedle Patch Based on Functionalized Alginate and Chitosan for Long-Term Self-Regulated Insulin Delivery

Glucose-Responsive Microneedle Patch with High Insulin Loading Capacity for Prolonged Glycemic Control in Mice and Minipigs

Microneedles with Two-Stage Glucose-Sensitive Controlled Release for Long-Term Insulin Delivery.

Microneedle Patches Loaded with Nanovesicles for Glucose Transporter-Mediated Insulin Delivery.

Microneedle-array patch with pH-sensitive formulation for glucose-responsive insulin delivery

Drug Delivery: Microneedles Integrated with Pancreatic Cells and Synthetic Glucose‐Signal Amplifiers for Smart Insulin Delivery (adv. Mater. 16/2016)

Hypoxia and H2o2 Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery

"Smart" Matrix Microneedle Patch Made of Self‐Crosslinkable and Multifunctional Polymers for Delivering Insulin On‐Demand

H2O2-Responsive Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin Delivery.

Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs

Glucose-responsive insulin microneedle patches for long-acting delivery and release visualization

Cross-Linking-Density-Changeable Microneedle Patch Prepared from a Glucose-Responsive Hydrogel for Insulin Delivery

Microneedles Integrated with Pancreatic Cells and Synthetic Glucose‐Signal Amplifiers for Smart Insulin Delivery

Microneedle Patch Prepared from a Hydrogel by a Mild Method for Insulin Delivery

Glucose-responsive microneedle patch for closed-loop dual-hormone delivery in mice and pigs

Glucose-responsive Microgels Integrated with Enzyme Nanocapsules for Closed-Loop Insulin Delivery.

Closed-Loop Diabetes Minipatch Based on a Biosensor and an Electroosmotic Pump on Hollow Biodegradable Microneedles